For more than four decades, patients with gastroparesis — a condition where the stomach cannot empty food at a normal pace — have been stuck with exactly one FDA-approved drug: metoclopramide, a medication so fraught with neurological side effects that it carries a black box warning. That drought may finally be ending. A nasal spray formulation called GIMOTI now offers a different delivery method for patients who cannot keep oral pills down, and a promising pipeline drug called naronapride is in late-stage clinical trials with a mechanism of action that could represent a genuine leap forward. Meanwhile, the American Gastroenterological Association published its first-ever clinical practice guideline for gastroparesis in 2025, a move that underscored just how neglected this condition has been by the medical establishment.
Consider a patient with diabetic gastroparesis who vomits so frequently that swallowing a pill is unreliable at best. Before GIMOTI’s approval, her options were limited to a medication she often could not absorb. Now she has a nasal spray alternative, though the active ingredient remains the same metoclopramide with the same safety concerns. Her story is not unusual — up to 5 million Americans are estimated to have gastroparesis, with a prevalence of roughly 267.7 per 100,000 US adults, and women are four times more likely to be affected than men. This article examines what drugs are actually available today, what failed, what is coming through the pipeline, and what the new AGA guideline means for the millions of people living with stomach paralysis.
Table of Contents
- What Drug Options Do Patients With Gastroparesis Finally Have in 2026?
- GIMOTI Nasal Spray — A New Delivery Route, but the Same Old Drug
- The Tradipitant Story — How a Promising Gastroparesis Drug Was Rejected
- Naronapride — The Pipeline Drug That Could Change Everything
- Why the 2025 AGA Guideline Matters — and What It Reveals
- Other Drugs in the Pipeline and Why They Stalled
- What Comes Next for Gastroparesis Treatment
- Conclusion
- Frequently Asked Questions
What Drug Options Do Patients With Gastroparesis Finally Have in 2026?
The honest answer is still frustratingly limited, but the landscape is shifting. Metoclopramide, a D2 dopamine receptor antagonist first approved decades ago, remains the only FDA-approved drug for gastroparesis treatment in the United States. It works by increasing stomach contractions and relaxing the valve between the stomach and small intestine, helping food move through. The typical dosing is 5 mg before meals, sometimes increased to 10 mg before meals. But in February 2009, the FDA slapped a black box warning on the drug for the risk of tardive dyskinesia — irreversible involuntary movements of the face, tongue, or extremities that can persist even after the drug is stopped. Treatment should not exceed 12 weeks except in rare cases where the therapeutic benefit is judged to outweigh the risk of developing this permanent movement disorder. That black box warning changed prescribing behavior dramatically.
Before it was issued, 69.8 percent of gastroparesis patients received metoclopramide. Afterward, that figure plummeted to just 23.7 percent. Many physicians simply stopped prescribing it, leaving patients with no approved pharmacological option at all. Some turned to off-label alternatives like domperidone, which is not FDA-approved and must be obtained through the FDA’s expanded access program, or erythromycin, an antibiotic that happens to stimulate stomach motility but loses effectiveness within weeks due to tachyphylaxis. The gap between what patients need and what medicine has provided is enormous. The primary causes of gastroparesis break down as follows: diabetes accounts for 57.4 percent of cases, surgery for 15.0 percent, medication side effects for 11.8 percent, and unknown or idiopathic causes for 11.3 percent. For readers of this site who care for someone with dementia, it is worth noting that diabetes is a significant risk factor for both cognitive decline and gastroparesis, and that the medications used to manage various conditions in elderly patients can themselves cause or worsen delayed gastric emptying. The intersection of brain health and gut motility is more relevant than many caregivers realize.
GIMOTI Nasal Spray — A New Delivery Route, but the Same Old Drug
GIMOTI, developed by Evoke Pharma, is the only FDA-approved nasal spray formulation of metoclopramide, indicated for adults with acute and recurrent diabetic gastroparesis. Its value proposition is straightforward: if your stomach is paralyzed and you are vomiting, absorbing an oral pill is unreliable. A nasal spray bypasses the gut entirely, delivering the drug through the nasal mucosa directly into the bloodstream. For patients who have struggled with inconsistent absorption of oral metoclopramide, this represents a meaningful practical improvement. The commercial trajectory of GIMOTI suggests growing adoption. Net product sales in the third quarter of 2025 reached $4.3 million, up 60 percent year-over-year, with full-year 2025 guidance of approximately $16 million. Evoke Pharma received a new U.S.
patent in August 2025 extending exclusivity to November 2038, and in November 2025, the company entered a merger agreement with QOL Medical — a move that could expand GIMOTI’s commercial reach. However, patients and caregivers should understand a critical limitation: GIMOTI is still metoclopramide. It carries the same black box warning for tardive dyskinesia, the same 12-week recommended treatment cap, and the same risk profile. If a patient had problems with oral metoclopramide due to side effects rather than absorption issues, GIMOTI does not solve that problem. For elderly patients, particularly those with dementia or Parkinson’s disease, this distinction matters enormously. Tardive dyskinesia symptoms can be mistaken for progression of an underlying neurological condition, delaying recognition that a medication is causing harm. Caregivers should discuss with the prescribing physician whether the specific benefit of nasal delivery justifies the neurological risks in their loved one’s case, and they should watch closely for any new involuntary movements of the mouth, tongue, or limbs during treatment.
The Tradipitant Story — How a Promising Gastroparesis Drug Was Rejected
One of the most closely watched gastroparesis drug candidates in recent years was tradipitant, a neurokinin-1 receptor antagonist developed by Vanda Pharmaceuticals. The NK-1 pathway is centrally involved in nausea and vomiting signaling, making it a logical target for a condition defined by those symptoms. Early trial results generated genuine optimism among patients and gastroenterologists who had been waiting decades for something new. That optimism was crushed in September 2024 when the FDA issued a Complete Response Letter rejecting Vanda’s gastroparesis application for tradipitant, citing a lack of substantial evidence of efficacy. The pivotal Study 3301 did not demonstrate statistical significance between tradipitant and placebo for its primary endpoint — change in nausea severity. The FDA went further in January 2025, formally proposing to refuse approval in the Federal Register.
Vanda accepted the opportunity for a hearing on January 27, 2025, but has since paused the gastroparesis legal battle. Tradipitant was, however, approved on December 30, 2025, under the brand name NEREUS — but for prevention of vomiting induced by motion, not for gastroparesis. It became the first new motion sickness drug in more than 40 years, a milestone that only deepens the irony for gastroparesis patients who watched their hoped-for treatment succeed in a different indication. Vanda has pivoted tradipitant toward a Phase 3 trial for GLP-1 receptor agonist-induced nausea — the nausea and vomiting caused by drugs like Wegovy and Ozempic. Given the explosive growth of the GLP-1 market, this represents a potentially lucrative commercial opportunity. But for gastroparesis patients, it is another reminder that their condition remains an afterthought.
Naronapride — The Pipeline Drug That Could Change Everything
If there is a realistic reason for optimism, it is naronapride, developed by Renexxion and Dr. Falk Pharma. Unlike existing treatments that target a single receptor, naronapride is an oral, locally acting pan-GI prokinetic with a dual mechanism: it combines 5-HT4 receptor agonism with D2 receptor antagonism. In plain language, it both stimulates the serotonin receptors that promote gut motility and blocks the dopamine receptors that slow it down — attacking the problem from two directions simultaneously. It acts locally in the gastrointestinal tract rather than systemically, which in theory should reduce the risk of central nervous system side effects like tardive dyskinesia. The Phase 2b MOVE-IT study completed enrollment in May 2025 with 320 patients across global clinical sites, evaluating three doses — 10 mg, 20 mg, and 40 mg taken three times daily — against placebo over 12 weeks. The FDA cleared the investigational new drug application, allowing expansion to U.S.
clinical sites. Topline results were expected in the second half of 2025, meaning they may be available or imminent as of early 2026. The drug has demonstrated a favorable safety profile across four Phase 2 trials and eight Phase 1 trials to date. The comparison with metoclopramide is instructive. Metoclopramide is also a D2 antagonist, but it crosses the blood-brain barrier and acts centrally, which is what causes the tardive dyskinesia risk. Naronapride’s locally acting design could potentially offer the same motility benefits without the neurological trade-off. However, until Phase 3 data are in hand and the FDA reviews a new drug application, this remains a promising hypothesis rather than a proven therapy. Gastroparesis patients have been burned by promising candidates before — tradipitant’s failure is fresh evidence of how the gap between mechanistic logic and clinical trial results can swallow hope whole.
Why the 2025 AGA Guideline Matters — and What It Reveals
The American Gastroenterological Association published its first-ever clinical practice guideline for gastroparesis management in 2025, and the most telling detail is not what it recommends but how it qualifies those recommendations. Every single recommendation was conditional with low certainty of evidence. This is the AGA effectively saying: we have been treating millions of patients with gastroparesis for decades, and we still do not have high-quality evidence for how best to do it. The guideline conditionally recommends metoclopramide, with an efficacy assessment at four to eight weeks to decide whether to continue treatment. The guideline also emphasized the lack of FDA-approved alternatives and the need for shared decision-making between physicians and patients given the side effect risks.
For caregivers managing gastroparesis in someone with dementia, this shared decision-making framework is crucial. A person with cognitive impairment may not be able to report early symptoms of tardive dyskinesia — subtle lip smacking, tongue protrusion, repetitive chewing movements — making the caregiver’s role as an observer essential. The AGA’s emphasis on reassessing treatment at four to eight weeks provides a concrete timeline that caregivers should mark on their calendar and bring up proactively with the treating physician. A broader warning applies here: the low certainty of evidence behind all gastroparesis treatment recommendations means that much of current management relies on clinical judgment, off-label prescribing, and trial-and-error. Patients and caregivers should expect a process of experimentation rather than a straightforward prescription, and they should not interpret a lack of immediate improvement as a failure of effort by their medical team.
Other Drugs in the Pipeline and Why They Stalled
Beyond naronapride and tradipitant, a handful of other compounds have been explored for gastroparesis with mixed results. Relamorelin, a ghrelin receptor agonist, showed genuine promise in trials involving patients with diabetic gastroparesis. It reduced core gastroparesis symptoms and was generally well-tolerated with a low neurological and cardiovascular risk profile — a meaningful advantage over metoclopramide. However, its development timeline has been prolonged, and it has not yet reached the market.
Felcisetrag, another candidate, demonstrated the ability to accelerate gastric transit in early studies. Its fatal competitive flaw is the route of administration: it requires intravenous delivery. For a chronic condition that patients must manage daily and indefinitely, an IV drug is impractical for the vast majority of real-world patients. Development of felcisetrag for gastroparesis appears to have been discontinued, reinforcing the reality that even drugs that work pharmacologically can fail commercially or logistically. The lesson for patients tracking the pipeline is to pay attention not just to efficacy data but to how a drug is given, how often, and at what cost.
What Comes Next for Gastroparesis Treatment
The next 12 to 24 months could be the most consequential period for gastroparesis drug development in a generation. Naronapride’s Phase 2b results, if positive, would likely trigger a Phase 3 program that could bring a genuinely new mechanism of action to market. The growing GLP-1 agonist market — with tens of millions of patients taking Wegovy, Ozempic, and related drugs — is creating a secondary wave of gastroparesis-like symptoms that is attracting pharmaceutical investment to the motility space for the first time in years. Drug companies that previously saw gastroparesis as too small a market are now recalculating. For patients and caregivers living with gastroparesis today, the practical reality has not yet caught up with the pipeline optimism.
Metoclopramide, with all its limitations, remains the backbone of pharmacological treatment. GIMOTI offers a delivery advantage for a subset of patients. Dietary modifications, gastric electrical stimulation, and pyloric interventions fill some of the gap. But the 2025 AGA guideline’s conditional recommendations and low certainty ratings are a blunt acknowledgment that the field has underserved these patients for far too long. The hope is that acknowledgment accelerates change.
Conclusion
Gastroparesis patients in 2026 have marginally more than they did a decade ago, but far less than they deserve. Metoclopramide remains the only FDA-approved treatment, carrying a black box warning that has justifiably scared many patients and physicians away. GIMOTI provides a nasal spray delivery option for those with diabetic gastroparesis who cannot reliably absorb oral medications, though it does not solve the fundamental safety concerns. Tradipitant’s rejection for gastroparesis was a painful setback, even as it found approval for motion sickness under a different name. Naronapride stands as the most credible near-term hope for a drug that could treat gastroparesis without the neurological baggage of existing options.
For caregivers on this site who are managing gastroparesis alongside dementia or other neurological conditions, vigilance is the most practical takeaway. Know the signs of tardive dyskinesia. Insist on the four-to-eight-week reassessment the AGA guideline recommends. Ask the prescribing physician specifically about the risks of metoclopramide in patients with existing neurological conditions. And stay informed about naronapride and other pipeline developments — because after 40 years of therapeutic stagnation, the science may finally be catching up to the need.
Frequently Asked Questions
What is the only FDA-approved drug for gastroparesis?
Metoclopramide (brand name Reglan) is the sole FDA-approved drug for gastroparesis in the United States. It has been the only approved option for over 40 years. GIMOTI is an FDA-approved nasal spray formulation of metoclopramide specifically for diabetic gastroparesis, but the active ingredient is the same drug.
Why do doctors hesitate to prescribe metoclopramide for gastroparesis?
In February 2009, the FDA issued a black box warning — the most serious type of safety alert — for metoclopramide due to the risk of tardive dyskinesia, a condition involving irreversible involuntary movements of the face, tongue, or extremities. Treatment is recommended not to exceed 12 weeks. Prescribing rates dropped from 69.8 percent to 23.7 percent of gastroparesis patients after the warning was issued.
Was tradipitant approved for gastroparesis?
No. The FDA rejected tradipitant for gastroparesis in September 2024, citing insufficient evidence of efficacy. The pivotal trial failed to show a statistically significant difference from placebo in reducing nausea severity. Tradipitant was later approved in December 2025 under the brand name NEREUS, but only for prevention of motion-induced vomiting — a different condition entirely.
What is naronapride and when might it be available?
Naronapride is an oral, locally acting prokinetic drug with a dual mechanism — 5-HT4 receptor agonism and D2 receptor antagonism — being developed by Renexxion and Dr. Falk Pharma. Its Phase 2b trial (MOVE-IT) enrolled 320 patients and completed enrollment in May 2025, with topline results expected in the second half of 2025. If successful, it would still need to complete Phase 3 trials and FDA review before reaching patients, likely placing availability several years away.
Is gastroparesis related to dementia or brain health?
Diabetes is a major risk factor for both gastroparesis (accounting for 57.4 percent of cases) and cognitive decline. Additionally, the primary drug used to treat gastroparesis — metoclopramide — carries neurological risks including tardive dyskinesia, which can be particularly dangerous for patients who already have neurological conditions. Caregivers of dementia patients should be especially watchful for new involuntary movements during treatment.
What did the 2025 AGA guideline recommend for gastroparesis?
The American Gastroenterological Association’s first-ever gastroparesis guideline conditionally recommended metoclopramide with efficacy assessment at four to eight weeks. Notably, every recommendation in the guideline was conditional with low certainty of evidence, reflecting the enormous gaps in high-quality research for this condition. The guideline stressed shared decision-making between patients and physicians given the limited options and significant side effect risks.
